Puma biotechnology neratinib 2025
Puma biotechnology neratinib 2025
Puma biotechnology neratinib 2025
Puma biotechnology neratinib 2025
Puma biotechnology neratinib 2025
Puma biotechnology neratinib 2025

Puma biotechnology neratinib 2025

Puma biotechnology neratinib 2025, Puma Biotechnology Reports Results of PB272 neratinib in P III NALA Trial for Patients with 2L HER2 Metastatic Breast Cancer ASCO2019 2025

$53.00

SKU: 7501752

Colour
  • Puma Biotechnology Biotechnology The Pharmaletter The Pharmaletter
  • Puma Biotechnology Biotechnology The Pharmaletter The Pharmaletter
  • A New Drug on the Horizon for HER2 Breast Cancer Patients Avise Analytics
  • Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2 Mutant HR Positive Metastatic Breast Cancer at SABCS 2020 Business Wire
Out of stock
Personalised:
: ( x )
Personalisation:
Edit
Remove Personalisation
Frasers Plus

Buy now.

Pay later.

Earn rewards

Representative APR: 29.9% (variable)

Credit subject to status. Terms apply.

Missed payments may affect your credit score

FrasersPlus